Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Exosome-like nanoparticles from intestinal mucosal cells carry prostaglandin E2 and suppress activation of liver NKT cells.

Deng ZB, Zhuang X, Ju S, Xiang X, Mu J, Liu Y, Jiang H, Zhang L, Mobley J, McClain C, Feng W, Grizzle W, Yan J, Miller D, Kronenberg M, Zhang HG.

J Immunol. 2013 Apr 1;190(7):3579-89. doi: 10.4049/jimmunol.1203170. Epub 2013 Mar 6. Erratum in: J Immunol. 2016 Jun 1;196(11):4832.

2.

Intestinal mucus-derived nanoparticle-mediated activation of Wnt/β-catenin signaling plays a role in induction of liver natural killer T cell anergy in mice.

Deng ZB, Zhuang X, Ju S, Xiang X, Mu J, Wang Q, Jiang H, Zhang L, Kronenberg M, Yan J, Miller D, Zhang HG.

Hepatology. 2013 Mar;57(3):1250-61. doi: 10.1002/hep.26086. Epub 2013 Feb 11. Erratum in: Hepatology. 2016 Apr;63(4):1404.

3.

α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.

Huang JR, Tsai YC, Chang YJ, Wu JC, Hung JT, Lin KH, Wong CH, Yu AL.

J Immunol. 2014 Feb 15;192(4):1972-81. doi: 10.4049/jimmunol.1302623. Epub 2014 Jan 24.

4.

A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by alpha-galactosylceramide.

Cao Z, Dhupar R, Cai C, Li P, Billiar TR, Geller DA.

J Immunol. 2010 Aug 15;185(4):2536-43. doi: 10.4049/jimmunol.1000092. Epub 2010 Jul 12.

5.

Glycolipid antigen induces long-term natural killer T cell anergy in mice.

Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L.

J Clin Invest. 2005 Sep;115(9):2572-83.

6.

PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.

Wang XF, Lei Y, Chen M, Chen CB, Ren H, Shi TD.

J Viral Hepat. 2013 Apr;20 Suppl 1:27-39. doi: 10.1111/jvh.12061.

PMID:
23458522
7.

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.

Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C, Zhou D.

Vaccine. 2009 May 26;27(25-26):3484-8. doi: 10.1016/j.vaccine.2009.01.047. Epub 2009 Feb 5.

PMID:
19200815
8.

Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.

Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, Sastry J.

Eur J Immunol. 2011 Nov;41(11):3312-22. doi: 10.1002/eji.201041359. Epub 2011 Sep 19.

9.

Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.

Tohn R, Blumenfeld H, Haeryfar SM, Veerapen N, Besra GS, Porcelli SA, Delovitch TL.

Clin Exp Immunol. 2011 Apr;164(1):26-41. doi: 10.1111/j.1365-2249.2011.04323.x. Epub 2011 Mar 1.

10.

Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.

Iyoda T, Ushida M, Kimura Y, Minamino K, Hayuka A, Yokohata S, Ehara H, Inaba K.

Int Immunol. 2010 Nov;22(11):905-13. doi: 10.1093/intimm/dxq444.

PMID:
21118907
11.

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.

Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T.

J Exp Med. 1999 Apr 5;189(7):1121-8.

12.

Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.

Biburger M, Tiegs G.

J Leukoc Biol. 2008 Jul;84(1):264-79. doi: 10.1189/jlb.0607352. Epub 2008 Apr 11.

PMID:
18407967
13.

Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.

Inui T, Nakagawa R, Ohkura S, Habu Y, Koike Y, Motoki K, Kuranaga N, Fukasawa M, Shinomiya N, Seki S.

J Immunol. 2002 Dec 1;169(11):6127-32.

14.

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

Kakimi K, Guidotti LG, Koezuka Y, Chisari FV.

J Exp Med. 2000 Oct 2;192(7):921-30.

15.

Valpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes.

Ohtaki H, Ito H, Ando K, Ishikawa T, Saito K, Imawari M, Yokochi T, Moriwaki H, Seishima M.

Biochem Biophys Res Commun. 2009 Jan 16;378(3):579-83. doi: 10.1016/j.bbrc.2008.11.075. Epub 2008 Dec 3.

PMID:
19056341
16.

Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.

Sullivan BA, Kronenberg M.

J Clin Invest. 2005 Sep;115(9):2328-9.

17.

Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.

Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, Abo T.

Eur J Immunol. 2000 Jul;30(7):1919-28.

18.

Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.

Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI.

Blood. 2002 Feb 15;99(4):1259-66.

19.

Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.

Wu J, Shin J, Xie D, Wang H, Gao J, Zhong XP.

J Immunol. 2014 Mar 15;192(6):2643-50. doi: 10.4049/jimmunol.1302076. Epub 2014 Feb 14.

20.

Effects of cyclosporin A on the activation of natural killer T cells induced by alpha-galactosylceramide.

Kajiwara T, Tomita Y, Okano S, Iwai T, Yasunami Y, Yoshikai Y, Nomoto K, Yasui H, Tominaga R.

Transplantation. 2007 Jan 27;83(2):184-92.

PMID:
17264815

Supplemental Content

Support Center